As Edmond de Rothschild Investment Partners begins its second decade, it is moving to increase its footprint outside of Europe. With 18 life science exits since its inception in 2002, EdRIP believes its ability to consistently provide liquidity will allow the firm to expand a fledgling international LP base and the scope of its investments in Asia and the U.S.

EdRIP is the private equity arm of La Compagnie Financiere Edmond de Rothschild Banque, which takes a 10% stake in all EdRIP investments.